H-Cyte Inc. has completed its acquisition of Jantibody, a novel cancer immunotherapeutic agent that has demonstrated promising efficacy in controlling ovarian cancer and mesothelioma in preclinical models.

Arcutis Biotherapeutics Inc. has entered into an agreement to acquire Ducentis Biotherapeutics Inc., a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases.